Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Blood Advances|October 4, 2021
Type 1 interferon to prevent leukemia relapse after allogeneic transplantationJohn M Magenau, Dan Peltier, Mary Riwes, et al.
Blood Advances|April 8, 2025
PD-1 Inhibition for Relapse after Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic SyndromeJohn M Magenau, David G Frame, Mary Mansour Riwes, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 3, 2019
Assessment of Individual versus Composite Endpoints of Acute Graft-versus-Host Disease in Determining Long-Term Survival after Allogeneic TransplantationJohn Magenau, Thomas Braun, Erin Gatza, et al.
The Journal of Biological Chemistry|May 29, 2026
Dysregulated HELLS expression alters cellular processes and serves as a potential prognostic marker in acute myeloid leukemiaSwati Madhulika, T Sayamsmruti Panda, Priyanka Samal, et al.
Blood Advances|October 22, 2024
Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysisAmneet Bajwa, Qiuhong Zhao, Marcus Geer, et al.
Blood Cancer Discovery|April 17, 2026
A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaJustin M Darrah, Indumathy Varadarajan, Amitkumar Mehta, et al.
Frontiers in Immunology|July 1, 2024
Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin's lymphomaDavid G Frame, Marcus Geer, Salena Kasha, et al.
Nature Medicine|October 19, 2023
Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantationMary M Riwes, Jonathan L Golob, John Magenau, et al.
The Lancet. Haematology|December 31, 2021
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trialRobert Zeiser, Gérard Socié, Mark A Schroeder, et al.
Blood|August 30, 2023
A phase 2 trial of CD24Fc for prevention of graft-versus-host diseaseJohn Magenau, Samantha Jaglowski, Joseph Uberti, et al.
Pageof 4